August 3, 2012

The novel GLP ‐1‐gastrin dual agonist, ZP3022 , increases β‐cell mass and prevents diabetes in db/db mice

Key Points

Key points are not available for this paper at this time.

Abstract

The novel GLP-1-gastrin dual agonist, ZP3022, improved glycaemic control in db/db mice, and pancreatic islet and β-cell mass increased significantly following treatment with ZP3022 compared with vehicle.

The novel GLP ‐1‐gastrin dual agonist, ZP3022 , increases β‐cell mass and prevents diabetes in db/db mice

Key Points

Abstract

Cite This Study